Second-generation antipsychotic long-acting injections in bipolar disorder: Systematic review and meta-analysis by Prajapati, Asta R. et al.
Bipolar Disorders. 2018;1–10.	 wileyonlinelibrary.com/journal/bdi	 | 	1
 
Received:	19	January	2018  |  Revised:	20	July	2018  |  Accepted:	30	September	2018
DOI: 10.1111/bdi.12707
R E V I E W  A R T I C L E
Second‐generation antipsychotic long‐acting injections in 
bipolar disorder: Systematic review and meta‐analysis
Asta R. Prajapati1  | Jon Wilson2 | Fujian Song3 | Ian Maidment4
1Pharmacy	Department,	Norfolk	and	Suffolk	
NHS	Foundation	Trust,	Norwich,	UK
2Research	Department,	Norfolk	and	Suffolk	
NHS	Foundation	Trust,	Norwich,	UK
3Norwich	Medical	School,	University	of	East	
Anglia,	Norwich,	UK
4School	of	Life	and	Health	Sciences,	Aston	
University,	Birmingham,	UK
Correspondence
Asta	R.	Prajapati,	Pharmacy	Department,	
Norfolk	and	Suffolk	NHS	Foundation	Trust,	
Hellesdon	Hospital,	Norwich,	UK.
Email:	asta.prajapati@nsft.nhs.uk
Funding information
This	research	received	no	specific	grant	from	
any	funding	agency	in	public,	commercial	or	
not‐for‐profit	sectors.
Abstract
Background:	Non‐adherence	is	a	significant	problem	in	bipolar	disorder.	Second‐gen‐
eration	antipsychotics	(SGA)	long‐acting	injections	(LAIs)	may	improve	adherence	in	
bipolar	 disorder	 and	may	 prevent	 relapses.	 However,	 the	 evidence	 is	 limited	 and	
conflicting.
Objective:	The	objective	of	this	study	was	to	evaluate	efficacy	and	safety	of	SGA	
LAIs	in	bipolar	disorder.
Method:	Systematic	review	and	meta‐analysis	of	randomised	controlled	trials	(RCTs)	
(≥6	months	duration)	investigating	safety	and	efficacy	of	SGA	LAIs	for	bipolar	disor‐
der.	We	searched	Pubmed,	Embase,	CINAHL,	Cochrane,	PsycINFO,	LiLACS,	www.
clinicaltrials.gov	up	to	October	2016.	We	also	contacted	the	manufacturers	of	SGA	
LAIs.	Primary	efficacy	and	safety	outcomes	were	relapse	rate	and	all‐cause	discon‐
tinuation	respectively.
Results:	Total	of	seven	RCTs	 (n	=	1192)	were	 included.	SGA	LAIs	show	superiority	
over	 placebo	 for	 study‐defined	 relapse	 rate	 (RR	=	0.58,	 95%	 CI	=	0.49‐0.68,	
P	<	0.00001)	 and	 all‐cause	 discontinuation	 (RR	=	0.72,	 95%	 CI	=	0.64‐0.82,	
P	<	0.00001).	However,	no	significant	difference	was	found	between	SGA	LAIs	and	
oral	active	control	for	relapse	rate	(RR	=	0.92,	P	=	0.79)	and	all‐cause	discontinuation	
(RR	=	1.2,	P	=	0.31).	 In	 terms	of	 secondary	outcomes,	 SGA	LAIs	 performed	better	
than	placebo	in	relapse	to	mania/hypomania,	young	mania	rating	scales	(YMRS),	clini‐
cal	global	 impression‐severity	 (CGI‐S),	montgomery‐asberg	depression	 rating	scale	
(MADRS).	 There	was	 no	 significant	 difference	 between	 SGA	 LAIs	 and	 oral	 active	
control	 regarding	relapse	 to	mania/hypomania,	YMRS,	CGI‐S,	extra‐pyramidal	side	
effects	(EPSEs),	weight	gain.	However,	the	active	control	performed	better	than	SGA	
LAIs	in	relapse	to	depression,	MADRS,	and	prolactin‐related	AEs.
Conclusions:	Current	evidence	is	very	limited	to	support	the	use	of	SGA	LAIs	(com‐
pared	to	oral	medication)	in	bipolar	disorder.	Further	high‐quality	studies,	particularly	
comparing	SGA	LAIs	with	active	control,	are	warranted.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial‐NoDerivs	License,	which	permits	use	and	distribution	in	
any	medium,	provided	the	original	work	is	properly	cited,	the	use	is	non‐commercial	and	no	modifications	or	adaptations	are	made. 
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1  | INTRODUC TION
Treatment	for	bipolar	disorder	should	aim	to	reduce	relapses,	prevent	
suicide,	minimise	resource	utilisation	and	societal	costs,	and	improve	
functioning.1‐3	 However,	 about	 40%	 of	 people	 with	 bipolar	 disor‐
der	do	not	adhere	to	their	prescribed	treatment.	Non‐adherence	is	
associated	with	increased	risk	of	relapse	and	suicide,	unfavourable	
outcomes,	 and	 admission	 to	 hospital.	 The	 probability	 of	 hospital‐
isation	 is	 five	 times	 or	 higher	 in	 non‐adherent	 patients	 compared	
to	 adherent	patients	with	bipolar	disorder.4	 Long‐acting	 injections	
(LAIs,	 also	known	as	depots)	may	 improve	adherence	and	 thereby	
patient	outcomes.	Evidence	from	studies	in	people	with	schizophre‐
nia	 suggests	 that	 antipsychotic	 LAIs	 reduce	 relapses,	 medication	
discontinuation	 rates,	 and	 admission	 to	 hospital	 compared	 to	 oral	
antipsychotics.5‐7	LAIs	have	some	clear	advantages	including	assur‐
ance	of	medication	administration	and	the	opportunity	to	intervene	
if	 patients	 stop	 treatment,	 and	 evidence	 from	 systematic	 review	
shows	patients	prefer	LAIs	to	oral.8	But	LAIs	could	also	cause	em‐
barrassment	for	some	patient	while	being	administered	and	could	be	
stigmatising	for	patients.9	Clinical	experience	and	evidence	suggest	
that	the	use	of	LAIs	for	bipolar	disorder	is	not	infrequent.2,10,11	None	
of	the	SGA	LAIs	is	licensed	for	bipolar	disorder	in	the	UK	and	the	EU	
although	 risperidone	 LAI	 and	more	 recently	 aripiprazole	 LAI	 have	
been	approved	in	the	US,	Canada,	and	Australia	for	bipolar	disorder.	
However,	evidence	base	for	efficacy	is	conflicting.3,12‐14	This	meta‐
analysis	 of	 RCTs	 (≥6	months	 duration)	 sought	 to	 address	whether	
there	is	sufficient	evidence	to	recommend	SGA	LAIs	in	patients	with	
bipolar	 disorder	 compared	 to	 placebo	 and	 active	 control.	 To	 our	
knowledge,	 this	 is	 the	 first	meta‐analysis	 focusing	on	SGA	LAIs	 in	
bipolar	disorder	which	included	more	than	one	SGA	LAI:	risperidone	
LAI	(RLAI)	and	aripiprazole	LAI	(ALAI).
2  | METHOD
The	study	was	registered	with	PROSPERO	(international	prospective	
register	of	systematic	reviews)	(CRD42015023948).	The	research	pro‐
tocol	was	based	on	PRISMA,	Preferred	Reporting	Items	for	Systematic	
Reviews	and	Meta‐Analyses,	statement	and	published	in	BMJ	Open.15
2.1 | Eligibility criteria
The	 study	 eligibility	 criteria	 were	 based	 on	 the	 PICOS	 framework;	
Participants,	Interventions,	Comparators,	Outcomes,	and	Study	design.
Any	 studies	 not	 meeting	 the	 following	 inclusion	 criteria	 were	
excluded:
•	 Participants:	patients	of	any	age	or	gender	with	bipolar	disorder	
using	any	validated	diagnostic	system,	for	example,	DSM‐IV:	296	
or	ICD	10:	F31.
•	 Interventions:	SGA	LAIs	in	bipolar	disorder
•	 Comparators:	 placebo,	 other	 antipsychotics,	mood	 stabiliser,	 or	
treatment	as	usual	(TAU)
•	 Outcome	measures:
o	 Primary	efficacy	outcome—study‐defined	relapse	rate
o	 Primary	safety	outcome—all‐cause	discontinuation
o	 Secondary	 outcomes	 included	 relapse	 to	 mania/hypomania,	
relapse	to	depression,	changes	 in	young	mania	rating	scales,	
montgomery‐asberg	 depression	 rating	 scale,	 clinical	 global	
impression‐severity,	 discontinuation	 due	 to	 adverse	 effect,	
the	proportion	of	patients	experiencing	extra‐pyramidal	side	
effects,	weight	gain,	and	prolactin‐related	adverse	effects.
•	 Study	design:	RCTs	with	or	without	double	blinding	with	a	mini‐
mum	duration	of	6	months.
2.2 | Data sources, search strategy, and 
study selection
The	following	search	strategy	was	employed	to	ensure	all	relevant	stud‐
ies	 assessing	 SGA	 LAIs	 in	 bipolar	 disorder	 were	 captured,	 data	 inde‐
pendently	extracted,	analysed,	verified,	and	quality	assessed.	Pubmed,	
Embase,	CINAHL,	Cochrane	Library,	PsycINFO,	LiLACS,	and	www.clini‐
caltrials.gov	were	searched	for	studies	published	between	January	2000	
and	October	2016	since	SGA	LAIs	only	came	to	the	market	after	2000.	
There	were	no	language	restrictions.	Any	relevant	studies	mentioned	in	
those	identified	studies	were	searched	manually,	for	example,	by	scoping	
the	references	listed.	Manufacturers	of	SGA	LAIs	were	contacted	for	any	
ongoing	or	unpublished	studies.	The	initial	search	was	carried	out	in	April	
2016	and	was	rerun	in	October	2016	which	resulted	in	30	more	studies	
being	identified.
The	search	strategy	consisted	of	the	following	three	domains:
a	 Disease:	bipolar*,	mood	disorder*,	mania*,	manic‐depression*,	hy‐
pomania*,	AND
b	 Treatment:	 antipsychotic*,	 neuroleptic*,	 psychotropic*,	 atypical*,	
second	 generation	 antipsychotic*,	 SGA*,	 aripiprazole,	 olanzapine,	
paliperidone,	risperidone,	AND
c	 Formulation:	depot*,	 long‐acting	 inject*,	LAI*,	prolonged	release	
inject*,	sustained	release	inject*
The	process	of	identifying,	screening	of	studies,	and	inclusion	
or	 exclusion	of	 those	 studies	 is	 shown	 in	 the	PRISMA	 flow	dia‐
gram	below	(see	Figure	1).
K E Y W O R D S
antipsychotic	depots,	antipsychotic	long‐acting	injection,	bipolar	disorder,	mental	health,	
meta‐analysis,	second‐generation	antipsychotic
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2.3 | Screening, data extraction, and analysis
ARP	screened	titles	of	all	retrieved	studies.	During	title	screening,	we	
excluded	only	definitely	non‐relevant	studies,	that	is,	studies	that	were	
not	in	human,	not	in	bipolar	patients,	not	an	RCT,	did	not	involve	SGA	
LAIs,	studies	published	before	2000,	retrospective	studies,	studies	of	
less	than	6	months’	duration	or	duplicates.	If	there	was	any	doubt,	the	
studies	were	 included	 in	stage	2	abstract	screening.	Abstracts	of	re‐
maining	studies	were	screened	against	prespecified	criteria	as	per	pub‐
lished	protocol15	by	ARP	and	JW	independently.	ARP	and	JW	screened	
full	 article	 of	 remaining	 studies.	 Any	 discrepancies	 were	 resolved	
through	further	discussion	or	via	third	reviewer	IM.
The	data	extraction	form	was	adopted	from	EPOC	(Effective	Practice	
and	Organisation	of	Care)	resources	for	review	authors	and	CONSORT	
(Consolidated	Standards	of	Reporting	Trials)	2010	checklist.	All	quantita‐
tive	data	(both	primary	and	secondary	outcome	measures)	for	meta‐anal‐
ysis	were	extracted	by	two	reviewers	(ARP	and	FS)	independently.	The	
remaining	data	were	extracted	by	ARP	and	JW	independently.
2.4 | Meta‐analytic method and quality assessment
The	RevMan	5	computer	program	was	used	for	undertaking	the	meta‐
analysis.	Primary	efficacy	and	safety	outcome	measure	were	presented	
as	RISK	Ratio	(RR).	Statistical	significance	was	set	at	0.05	with	P‐value	
<0.05	 considered	 statistically	 significant.	 The	 estimated	 effect	 size	
and	mean	difference	for	continuously	distributed	outcomes	were	pre‐
sented	with	95%	Confidence	Interval	 (CI).	The	analysis	was	based	on	
intention‐to‐treat	 (ie,	all	 randomly	allocated	patients	were	accounted	
for	the	analysis	of	outcomes)	where	the	data	were	available.	Study	het‐
erogeneity	was	measured	using	I2 statistics	with	values	of	50%	or	higher	
reflecting	considerable	heterogeneity.	Statistical	heterogeneity	across	
studies	was	tested	using	Chi‐square	or	Q	test.	We	employed	random	
effect	model	in	this	meta‐analysis.	Where	only	standard	error	(SE)	was	
given	but	 lacked	standard	deviation	 (SD),	we	calculated	SD	using	the	
formula,	SD	=	square	root	of	(n)	*	SE.
3  | RESULTS
A	 total	 of	 645	 studies	were	 found.	 The	 result	 from	each	 stage	of	
screening	is	shown	in	Prisma	flow	diagram	(See	Figure	1).
3.1 | Summary of included studies
Table	1	below	presents	summary	of	studies	included	in	the	meta‐anal‐
ysis.	All	studies	included	18‐	to	70‐year‐old	male	and	female	patients.	
(See	Supporting	information	Table	S2	for	more	detailed	summary).
F I G U R E  1  PRISMA	flow	diagram	of	
studies
4  |     PRAJAPATI eT Al.
3.2 | Primary Outcomes
The	meta‐analysis	included	seven	RCTs	(n	=	1192),	of	which	three	were	
open	label3,17,18	and	four	were	double	blind.16,19‐21	Six	of	the	RCTs3,17‐21 
involved	the	use	of	risperidone	LAI	and	one	aripiprazole	LAI.16
For	 the	 meta‐analysis,	 studies	 were	 categorised	 into	 placebo	
controlled16,19‐21	 (n	=	4	 RCTs)	 and	 active	 controlled3,17,18,20	 (n	=	4	
RCTs).	Since	study	by	Vieta	et	al20	contained	three	arms	(risperidone	
LAI	vs	placebo	vs	oral	olanzapine),	this	study	appeared	in	both	cate‐
gories.	Risperidone	LAI	vs	placebo	(Vieta,	2012)	was	put	under	pla‐
cebo‐controlled	 category	while	 risperidone	 LAI	 vs	 oral	 olanzapine	
(Vieta,	2012	A)	under	active	controlled.
a	 Study‐defined	 relapse	 rate	 (placebo‐controlled	 studies	 only):	
Pooled	 data	 from	 four	 placebo‐controlled	 studies	 favour	 SGA	
LAIs	for	study‐defined	relapse	rate	as	shown	in	Figure	2	with	sta‐
tistically	significant	difference	between	the	two	groups.
b	 Primary	 safety	 outcome:	 All‐cause	 discontinuation	 (placebo‐con‐
trolled	studies	only).	All‐cause	discontinuation	was	significantly	less	
in	SGA	LAIs	group	compared	to	placebo	group	as	shown	in	Figure	3	
below.
c	 Primary	efficacy	outcome:	Study‐defined	 relapse	 rate	 (active‐con‐
trolled	 studies	 only).	 Active‐controlled	 studies	 evaluated	 various	
oral	 antipsychotics	 or	 TAU	 against	 risperidone	 LAI.	 There	was	 no	
statistically	 significant	 difference	 between	 SGA	 LAIs	 and	 active	
control	as	shown	in	Figure	4	below.	However,	there	was	significant	
heterogeneity.	Heterogeneity	reduced	to	0%	when	a	study	by	Vieta	
et	al20	was	removed.	This	led	to	a	significant	difference,	that	is,	SGA	
LAIs	performing	better	than	active	control	(RR	=	0.7,	95%	CI	=	0.53	
‐	0.94,	P	=	0.02),	but	this	would	have	removed	a	high	quality,	highest	
weighted	study	with	 two	 third	of	participants.	Thus,	 the	study	by	
Vieta	et	al	was	retained	in	the	analysis.
d	 All‐cause	discontinuation	(Active‐controlled	studies	only).	All‐cause	
discontinuation	was	 not	 significantly	 different	 between	 SGA	 LAIs	
group	and	active	control	group	as	shown	in	Figure	5	below.
3.3 | Sensitivity and subgroup analysis
We	 conducted	 sensitivity	 analysis	 excluding	 low‐quality	 studies	 (ie,	
Jadad	 score	 <4)	 for	 study‐defined	 relapse	 rate.	 Active	 control	 out‐
performed	SGA	LAI	 (n	=	261,	RR	=	1.63,	95%	CI	=	1.12‐2.37,	P	=	0.01,	
I2 =	NA)	 in	terms	of	study‐defined	relapse	rate	but	 included	only	one	
RCT.20	All	the	placebo‐controlled	studies	were	of	high	quality	and	SGA	
LAIs	performed	better	than	placebo	as	shown	in	Figure	2.
We	also	performed	the	following	analyses	by	subgroup	of	RCTs—
adjunctive	vs	monotherapy,	double	blind	vs	open	label,	rapid	cycling	
TA B L E  1  Summary	of	studies	included	in	meta‐analysis
Study (Ref) Study design No. of Participants No. completed study
Calabrese	et	al16 12	months,	RCT,	DB,	PC 133	ALAI	vs	133	Placebo 64	ALAI	vs	38	Placebo
Bobo	et	al17 12	months,	RCT,	OL,	AC 20	RLAI	+	TAU	vs	25	TAU	
Alone
16	RLAI	+	TAU	vs	19	TAU	Alone
Chengappa	et	al18 12	months,	Pilot,	RCT,	OL,	AC 21	RLAI	+	TAU	vs	18	Oral	
Antipsychotic	+	TAU
14	RLAI	+	TAU	vs	9	Oral	Antipsychotic	+	
TAU
Macfadden	et	al19 12	months,	RCT,	DB,	PC 65	RLAI	+	TAU	vs	59	Placebo	+	
TAU
39	RLAI	+	TAU	vs	25	Placebo	+	TAU
Quiroz	et	al21 24	months,	RCT,	DB,	PC 140	RLAI	vs	135	Placebo 72	RLAI	vs	31	Placebo
Vieta	et	al20 18	months,	RCT,	DB,	DD	PC/AC 131	RLAI	vs	133	Placebo	vs	
130	Oral	Olanzapine
53	RLAI	vs	38	Placebo	vs	77	Olanzapine
Yatham	et	al3 6	months,	Pilot,	RCT,	OL,	AC 23	RLAI	vs	26	Oral	
Antipsychotics
12	RLAI	vs	17	Oral	Antipsychotics
AC,	active	control;	ALAI,	aripiprazole	LAI;	CGI‐S,	clinical	global	impression‐severity;	DB,	double	blind;	DD,	double	dummy;	OL,	open	label;	PC,	placebo	
control;	RLAI,	risperidone	LAI;	TAU,	treatment	as	usual.
F I G U R E  2  Study‐defined	relapse	rate	(placebo‐controlled	studies	only)
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vs	 non‐rapid	 cycling—for	 study‐defined	 relapse	 rates	 in	 placebo‐
controlled	and	active‐controlled	studies.
Placebo‐controlled	 studies	 show	 SGA	 LAIs	 better	 than	 placebo	
both	as	an	adjunctive	 (RR	=	0.5,	95%	CI	=	0.3‐0.85,	P	=	0.01)	and	as	
monotherapy	(RR	=	0.58,	95%	CI	=	0.49‐0.69,	P	<	0.00001).	However,	
active	 control	 performed	 better	 than	 SGA	 LAIs	 as	 monotherapy	
(RR	=	1.63,	 95%	 CI	=	1.12‐2.37,	 P	=	0.01)	 and	 SGA	 LAIs	 performed	
better	as	an	adjunctive	(RR	=	0.70,	95%	CI	=	0.53‐0.94,	P	=	0.02).
Double‐blind	studies	show	a	statistically	significant	improvement	of	
SGA	LAIs	over	placebo	(RR	=	0.58,	95%	CI	=	0.49‐0.68,	P	<	0.00001),	
but	 active	 control	 performed	 better	 than	 SGA	 LAIs	 (RR	=	1.63,	 95%	
CI	=	1.12‐2.37,	 P	=	0.01).	 Three	 open‐label	 studies3,17,18	 show	 SGA	
LAIs	 performing	 better	 than	 active	 control	 (n	=	133,	 RR	=	0.70,	 95%	
CI	=	0.53‐0.94,	P	=	0.02).
Studies	in	patients	with	rapid	cycling	bipolar	disorder	show	statis‐
tically	 significant	 improvement	with	 SGA	 LAIs	 compared	 to	 placebo	
(n	=	1RCT)	and	active	control	 (n	=	1RCT).	 In	nonrapid	cycling	studies,	
SGA	 LAI	 were	 superior	 to	 placebo	 (RR	=	0.58,	 95%	 CI	=	0.49‐0.69,	
P	<	0.00001)	 but	 not	 active	 control	 (RR	=	1.29,	 95%	 CI	=	0.97‐1.29,	
P	=	0.08).
3.4 | Secondary outcome measures
Secondary	 outcome	measures	 were	 analysed	 similar	 to	 the	 pri‐
mary	 outcome	 by	 dividing	 all	 RCTs	 into	 two	 groups:	 placebo	
controlled	(PC)	and	active	controlled	(AC).	The	results	from	meta‐
analysis	for	secondary	outcome	measures	are	presented	below	in	
Table	2.
It	 is	worth	highlighting	that	SGA	LAIs	performed	better	than	pla‐
cebo	only	in	relapse	to	mania/hypomania,	YMRS,	CGI‐S,	MADRS.	There	
was	no	significant	difference	between	SGA	LAIs	and	oral	active	control	
regarding	 relapse	 to	mania/hypomania,	 YMRS,	CGI‐S,	 EPSEs,	weight	
gain.	However,	the	active	control	performed	better	than	SGA	LAIs	in	
relapse	 to	depression,	MADRS,	 and	prolactin‐related	AEs.	These	are	
F I G U R E  3  All‐cause	discontinuation	(placebo‐controlled	studies	only)
F I G U R E  4  Study‐defined	Relapse	rate	(active‐controlled	studies	only)
F I G U R E  5  All‐cause	discontinuation	(active‐controlled	studies	only)
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TA B L E  2  Meta‐analysis	result	for	secondary	outcome	measures
Outcome
No. of
Effect size 95% CI I2 P‐valueRCTs Patients
PC:	Relapse	to	mania/
hypomania
4 929 RR	=	0.39 0.30	to	0.51 0% <0.00001
AC:	Relapse	to	mania/
hypomania
2 300 RR	=	0.83 0.29	to	2.36 80% 0.72
PC:	Relapse	to	depression 4 929 RR	=	1.07 0.79	to	1.45 0% 0.67
AC:	Relapse	to	depression 2 300 RR	=	1.83 1.05	to	3.19 0% 0.03
PC:	YMRS 4 922 MD	=	−5.05 −6.27	to	−3.84 0% <0.00001
AC:	YMRS 4 394 MD	=	−0.04 −1.41	to	1.33 0% 0.96
PC:	MADRS 3 656 MD	=	−1.55 −2.86	to	–0.25 0% 0.02
AC:	MADRS 3 345 MD	=	2.2 0.52	to	3.88 0% 0.01
PC:	CGI‐S 3 656 MD	=	−0.77 −1.01	to	−0.53 0% <0.00001
AC:	CGI‐S 4 394 MD	=	0.05 −0.39	to	0.49 59% 0.82
PC:	Discontinuation	due	to	AEs 4 929 RR	=	2.89 1.03	to	8.09 0% 0.04
AC:	Discontinuation	due	to	AEs 4 403 RR	=	1.63 0.6	to	4.45 0% 0.34
PC:	EPSEs 3 693 RR	=	1.69 1.16	to	2.45 0% 0.006
AC:	EPSEs 2 84 RR	=	1.06 0.43	to	2.65 0% 0.9
PC:	Weight	gain 4 960 RR	=	2.32 1.33	to	4.06 40% 0.003
AC:	Weight	gain 3 347 RR	=	0.86 0.59	to	1.26 0% 0.44
PC:	Prolactin	related	AEs 3 694 RR	=	3.43 1.13	to	10.39 37% 0.03
AC:	Prolactin	related	AEs 3 347 RR	=	5.75 2.03	to	16.29 0% 0.0010
AEs,	adverse	effects;	RR,	risk	ratio;	MD,	mean	difference.
TA B L E  3  Quality	assessment	of	studies	included	in	meta‐analysis
Questions Calabrese16 Bobo 17 Chengappa 18 Macfadden19 Quiroz 21 Vieta 20 Yatham 3
1.	Was	the	study	described	as	ran‐
domised?	Yes	=	1,	No	=	0
1 1 1 1 1 1 1
2.	Was	the	method	used	to	generate	the	
sequence	of	randomisation	described	
and	appropriate?	Yes	=	1,	No	=	0
1 1 0 1 1 1 1
3.	Was	the	study	described	as	double	
blind?	Yes	=	1,	No	=	0
1 0 0 1 1 1 0
4.	Was	the	method	of	double	blinding	
described	and	appropriate?	Yes	=	1,	
No	=	0
1 0 0 1 1 1 0
5.	Was	there	a	description	of	withdrawals	
and	dropouts?	Yes	=	1,	No	=	0
1 1 1 1 0 0 1
6.	Deduct	one	point	if	the	method	used	to	
generate	the	sequence	of	randomisation	
was	described	and	it	was	inappropriate.	
Described	but	inappropriate	=	−1,	
Described	and	appropriate	=	0
0 0 0 0 0 0 0
7.	Deduct	one	point	if	the	study	was	
described	as	double	blind,	but	the	
method	of	blinding	was	inappropriate.	
Described	but	inappropriate	=	−1,	
Described	and	appropriate	=	0
0 0 0 0 0 0 0
Total Jadad Score 5 3 2 5 4 5 3
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interesting	findings	as	most	guidelines	recommend	treatment	accord‐
ing	to	the	spectrum	of	the	disorder,	that	is,	manic	phase,	depressive	ep‐
isodes,	or	maintenance	treatment.
3.5 | Quality Assessment of Studies
Study	 quality	 was	 assessed	 by	 AP	 and	 JW	 independently	 using	 the	
Jadad	Scale	 (See	Table	3).	The	Jadad	scale	 is	a	commonly	used	scale	
for	quality	assessment	of	randomised	controlled	trials.	It	is	a	five‐point	
scale	with	seven	questions	with	a	higher	score	meaning	higher	quality.
No	 attrition	 or	 reporting	 bias	 was	 noted	 within	 individual	
RCTs.	 Publication	 bias	 was	 investigated	 using	 funnel	 plot,	 see	
Figure	6.
4  | DISCUSSION
4.1 | Primary outcome measures
Our	systematic	review	and	meta‐analysis	found	that	on	primary	out‐
come	measures,	that	is,	study‐defined	relapse	rate	and	all‐cause	dis‐
continuation,	SGA	LAIs	performed	better	than	placebo	but	not	when	
compared	with	oral	active	control.
It	 is	worth	 noting	 that	 three3,17,18	 of	 four	 active‐controlled	 stud‐
ies	are	open	label,	two3,18	of	them	are	pilot	studies	and	the	number	of	
patients	in	active	control	studies	is	less	than	half	that	of	placebo‐con‐
trolled	studies.	However,	 the	active‐controlled	study	by	Vieta	et	al20 
was	of	high	quality	(Jadad	score	=	5)	with	a	larger	sample	size	(n	=	260),	
in	which	SGA	LAI	was	less	effective	than	oral	olanzapine	(RR	1.63,	95%	
CI	=	1.12	to	2.37).	Study	by	Vieta	et	al20	contained	three	arms:	risper‐
idone	LAI,	placebo,	oral	olanzapine,	and	used	double	dummy,	that	 is,	
placebo	LAI	was	given	to	patient	assigned	to	oral	olanzapine	group	and	
placebo	oral	was	given	to	patients	assigned	to	risperidone	LAI	and	pla‐
cebo	LAI	group.
It	 is	 also	 argued	 that	 participants	 in	 the	 RCTs	 are	more	 likely	 to	
adhere	 to	 their	 oral	medication	 owing	 to	 extra	 care	 and	monitoring	
they	receive	during	studies	compared	to	real‐world	patients.	This	may	
have	favoured	the	active	control	group	and	can	be	a	limitation	of	RCT	
comparing	SGA	LAIs	with	oral	active	control.	This	limitation	could	be	
overcome	by	designing	double‐blind	RCTs	with	double	dummy,	that	is,	
giving	LAI	placebo	for	oral	active	control	group	and	giving	oral	placebo	
for	SGA	LAI	group	as	 in	 the	case	of	 the	study	by	Vieta	et	al.20	Such	
design	would	make	the	study	scientifically	more	robust	but	would	also	
add	significant	logistical	burden	to	the	RCT.	It	could	also	be	argued	that	
extra	care	and	monitoring	received	by	two	groups	(SGA	LAIs	and	oral	
active	control	group)	are	unlikely	to	be	huge,	and	thus,	their	effect	on	
adherence	is	likely	to	be	minimal.
4.2 | Secondary outcome measures
With	regard	to	the	secondary	outcome	measures	of	relapse	to	mania,	
YMRS,	and	CGI‐S,	SGA	LAIs	group	performed	only	better	than	placebo.	
There	was	no	significant	difference	between	SGA	LAIs	group	and	ac‐
tive	control	group	for	relapse	to	mania,	YMRS,	and	CGI‐S.	Active	con‐
trol	group	performed	better	than	SGA	LAI	group	regarding	relapse	to	
depression	and	MADRS.	This	finding	indicates	that	SGA	LAIs	are	not	a	
better	option	 for	patients	with	depression	dominant	bipolar	disorder	
and	suggest	that	the	benefits	of	SGA	LAIs	are	mainly	in	the	prevention	
of	mania,	similar	to	previous	findings.13,14,22
In	 terms	 of	 discontinuation	 due	 to	 adverse	 effects,	 EPSEs,	 and	
weight	gain,	placebo	was	safer	than	SGA	LAIs,	but	there	was	no	signifi‐
cant	difference	between	SGA	LAIs	and	active	control.	Both	placebo	and	
active	control	were	better	than	SGA	LAIs	for	prolactin‐related	adverse	
effects.
4.3 | Strengths and limitations of the study
Systematic	 review	 and	meta‐analysis	 of	 randomised	 controlled	 trials	
provide	the	highest	level	of	evidence	to	key	stakeholders.	Registration	
of	the	study	with	PROSPERO,	publication	of	the	study	protocol	in	the	
BMJ	Open,	extensive	and	broad	database	search	as	well	as	enquiry	with	
manufacturers,	finding	new	data	unavailable	in	the	previous	study	are	
some	of	the	key	strengths	of	this	meta‐analysis.	The	study	followed	the	
standard	 guideline	 for	 systematic	 reviews	 and	 meta‐analysis	 includ‐
ing	 those	of	PRISMA	statement,	CONSORT	checklist,	 and	Cochrane	
Handbook.
The	primary	outcomes	of	the	included	studies	were	wide	and	the	
definitions	of	the	primary	outcome	varied	among	the	studies	although	
our	 primary	 outcomes	were	 included	 in	 those	 studies.	 This	 is	 often	
an	issue	when	undertaking	a	meta‐analysis	where	data	are	combined	
which	is	nonidentical	but	which	is	clinically	reasonable	to	combine.	In	
addition,	this	 is	more	 likely	to	represent	the	real‐world	scenarios	and	
day‐to‐day	clinical	practice.	It	is	also	worth	noting	that	the	patients	in	
the	 selected	 studies	were	mix	 of	 rapid	 cycling,	mixed	 episodes,	 and	
varied	severity.	This	makes	our	findings	difficult	to	generalise	to	all	pa‐
tients	with	bipolar	disorder	without	taking	into	patient‐specific	diagno‐
sis,	polarity,	and	severity	of	the	disorder	into	account.	This	is	often	the	
challenge	in	RCTs	which	generally	includes	highly	selective	population	
making	it	difficult	to	generalise	the	evidence.
Cochrane	 does	 not	 recommend	 the	 use	 of	 scales	 for	 quality	 or	
risk	assessment.	However,	the	Jadad	scale	is	well	known,	simple,	and	
F I G U R E  6  Funnel	plot	of	all	active‐	and	placebo‐controlled	
studies
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easy	to	use.	It	contains	important	elements	that	have	empirically	been	
shown	to	correlate	with	the	risk	of	bias,23	and	thus,	Jadad	scale	was	
used	to	quality	assess	included	RCTs.
The	use	of	a	funnel	plot	to	assess	the	risk	of	bias	is	generally	used	
if	10	or	more	studies	are	included	in	the	meta‐analysis.	However,	we	
have	presented	a	funnel	plot	for	visual	inspection.	Notwithstanding	
the	small	number	of	studies	 (n	=	7),	visual	 inspection	of	the	funnel	
plot	(Figure	6)	does	not	suggest	publication	bias.	However,	it	is	worth	
emphasising	that	drug	manufacturers	funded	all	the	studies	included	
in	this	meta‐analysis	with	varying	degree	of	 influence	 in	the	study	
design,	conduct,	analysis,	reporting,	and	publication.
4.4 | Comparison to other studies
Details	of	literature	reviews	of	FGA	and	SGA	LAIs	in	bipolar	disorder	are	
described	by	Prajapati	et	al15	highlighting	the	differences	between	this	
study	and	previous	reviews.	Gigante	et	al13	and	Bond	et	al22 reviewed 
evidence	of	FGAs	and	SGA	LAIs	in	bipolar	disorder	and	concluded	that	
FGA	LAI	should	not	be	a	first	choice	due	to	risk	of	induction	of	depres‐
sion,	but	suggested	risperidone	LAI	 is	effective	 in	bipolar.	Samalin	et	
al14	carried	out	review	of	SGA	LAIs	in	bipolar	disorder	and	concluded	
that	risperidone	LAI	may	be	considered	for	maintenance	treatment	of	
bipolar	disorder	but	more	evidence	is	required.	While	these	literature	
reviews	provide	a	useful	overview	of	the	subject,	they	generally	 lack	
the	scientific	rigour	of	systematic	reviews.15	Recently,	Chou	et	al24 au‐
thored	an	article	titled	“A	Systemic	Review	and	Experts’	Consensus	for	
Long‐acting	Injectable	Antipsychotics	in	Bipolar	Disorder.”	This	was	an	
expert	consensus;	details	on	review	process	and	methodology	were	not	
reported.	In	addition,	all	aforementioned	studies	included	only	one	SGA	
LAIs,	namely,	risperidone	LAI,	and	none	included	meta‐analysis.
As	far	as	we	are	aware,	this	 is	the	first	meta‐analysis	focusing	on	
SGA	LAIs	in	bipolar	disorder	that	included	more	than	one	SGA	LAI.	The	
only	other	meta‐analysis	on	 this	 topic	was	by	Kishi	et	al25	and	 there	
are	significant	differences	between	the	two	meta‐analyses	in	terms	of	
included	studies,	methodology,	and	some	results.	Our	meta‐analysis	in‐
cludes	studies	of	risperidone	LAI	and	aripiprazole	LAI	whereas	Kishi	et	
al	included	only	risperidone	LAI.	This	is	important	because	aripiprazole	
is	also	one	of	the	recommended	treatment	options	for	bipolar	disorder	
and	aripiprazole	LAI	has	recently	been	licensed	for	bipolar	disorder	in	
the	US,	Canada,	and	Australia.
Unlike	Kishi	et	al,25	we	did	not	include	first‐generation	antipsychot‐
ics	(FGAs)	LAIs	in	our	meta‐analysis	because	they	are	not	considered	
the	preferred	choice	in	bipolar	disorder	due	to	the	risk	of	induction	of	
depression.13,22	Another	 reason	to	exclude	FGA	LAIs	 is	 that	patients	
with	bipolar	disorder	may	be	more	at	risk	of	EPSEs,	for	example,	when	
treated	 with	 high	 potency	 dopamine	 antagonists	 like	 haloperidol.26 
Accordingly,	successful	treatment	of	bipolar	disorder	without	extrapy‐
ramidal	symptoms	is	an	important	practical	clinical	objective.
Another	major	difference	between	the	two	studies	was	the	result	
of	relapse	to	depression	and	MADRS.	Kishi	et	al	show	no	statistically	
significant	difference	between	LAIs	and	active	control	(RR	=	1.25,	95%	
CI	=	0.6‐2.59,	P	=	0.55)	whereas	this	meta‐analysis	favours	active	con‐
trol	for	this	outcome	(RR	=	1.83,	95%	CI	=	1.05‐3.19,	P	=	0.03).	Similarly,	
MADRS	was	not	significantly	different	between	LAIs	and	active	control	
in	Kishi	et	al	(WMD	=	1.27,	95%	CI	=	0.59‐3.12,	P	=	0.18)	whereas	this	
study	favours	active	control	(MD	=	2.2,	95%	CI	=	0.52‐3.88,	P	=	0.01).	
This	 is	 likely	to	be	due	to	another	significant	difference	between	the	
two	meta‐analyses:	we	have	four	studies	in	each	group	(placebo	con‐
trolled	and	active	controlled)	compared	to	two	placebo‐controlled	and	
five	active‐controlled	studies	in	Kishi	et	al.25	This	was	due	to	two	rea‐
sons:	inclusion	of	FGA	LAIs	in	previous	meta‐analysis	and	the	allocation	
of	the	RCT	by	Macfadden19	as	an	active‐controlled	study	by	Kishi	et	al.	
The	study	by	Macfadden19	contained	two	arms	risperidone	LAI	+	TAU	
vs	Placebo	+	TAU	and	the	study	was	itself	titled	“…placebo	controlled…”	
in	their	publication.	Thus,	we	put	this	study	by	Macfadden19	et	al	under	
placebo‐controlled	group.	In	addition,	by	putting	RCT	by	Macfadden19 
into	an	active	control	group,	Kishi	et	al	may	have	diluted	the	positive	
effect	of	active	control	in	reducing	relapse	to	depression.
Another	difference	between	the	two	meta‐analyses	was	the	com‐
pleteness	 of	 the	 search.	 In	 addition	 to	 databases	 searched	 by	 Kishi	
et	 al	 (Medline,	 Cochrane	 Library,	 PsycINFO,	 Clinicaltrials.gov),	 we	
also	searched	LiLACS	(to	cover	literature	from	Latin	America	and	the	
Caribbean	which	may	not	have	been	covered	elsewhere),	EMBASE,	and	
CINAHL	 (to	 cover	 allied	 health	 professional	 literature).	 Furthermore,	
we	also	contacted	manufacturers	of	SGA	LAIs	for	further	published	or	
unpublished	studies	which	were	lacking	in	the	previous	meta‐analysis.
Both	 meta‐analyses	 show	 that	 placebo	 and	 active	 control	 were	
better	than	LAI	regarding	prolactin‐related	adverse	effects.	However,	
the	risk	ratio	of	prolactin‐related	adverse	events	in	this	meta‐analysis	
is	twice	that	was	in	Kishi	et	al	(RR	=	5.75	in	this	meta‐analysis	vs	2.66	
in	Kishi	et	al)	in	active	control	studies.	This	is	even	more	interesting	as	
active	control	studies	in	Kishi	et	al	contained	a	study	comparing	FGA	
LAI	(namely	flupentixol	decanoate)	which	is	known	to	cause	more	pro‐
lactin‐related	adverse	effect	than	SGA	LAIs	in	general.	This	difference	
between	the	two	meta‐analyses	is	again	likely	to	be	due	to	the	inclusion	
of	study	by	Macfadden	et	al19	into	active	control	group	by	Kishi	et	al.
Another	significant	difference	between	the	two	meta‐analyses	is	in	
their	conclusion.	The	main	conclusion	from	Kishi	et	al	was	that	“Long‐
acting	 injectable	antipsychotics	appear	beneficial	 for	 relapse	preven‐
tion	in	patients	with	rapid	cycling.”	Although	we	found	a	similar	result	
in	our	subgroup	analysis,	this	was	not	the	main	question	or	the	primary	
objective	of	the	published	meta‐analysis.	In	addition,	to	base	conclud‐
ing	remarks	on	two	RCTs	of	seven	is	difficult	to	justify;	more	so	when	
a	number	of	patients	to	draw	conclusion	was	less	than	one‐fifth	of	the	
total.	It	is	also	worth	noting	that	one	of	those	two	RCTs	was	active	con‐
trol	and	one	was	a	placebo	control.	So	combining	the	result	makes	it	
difficult	 to	 interpret	and	goes	against	 their	primary	analytical	design,	
that	is,	analysis	by	separating	studies	into	a	placebo	controlled	from	ac‐
tive	controlled.	We	conclude	that	currently	there	is	limited	evidence	to	
support	SGA	LAIs	in	bipolar	disorder,	when	compared	with	oral	active	
control.
4.5 | Future research
Further	 studies,	 particularly	 high‐quality	 active‐controlled	 stud‐
ies,	 are	warranted	 for	 conclusive	evidence.	There	are	 four	SGA	LAIs	
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(aripiprazole	LAI,	olanzapine	LAI,	paliperidone	LAI,	and	risperidone	LAI)	
on	the	market,	but	only	studies	involving	risperidone	LAI	and	aripipra‐
zole	LAI	were	found.	Further	research	on	SGA	LAIs,	preferably	com‐
paring	with	active	control	and	in	a	more	pragmatic,	real‐world	setting,	
will	add	significant	evidence	base	in	this	area.	Data	on	aripiprazole	LAI	
are	limited	due	to	there	being	only	a	single	RCT	and	lack	of	any	active	
control	studies.	Further	research	comparing	aripiprazole	LAI	with	ac‐
tive	control	is	warranted.	Research	on	paliperidone	LAIs	and	olanzapine	
LAI	also	merits	consideration.	However,	olanzapine	LAI	has	some	sig‐
nificant	 logistical	 issues	due	to	the	post	 injection	syndrome	and	thus	
requiring	patients	to	be	observed	for	3‐hour	post	injection.	This	may	be	
a	significant	barrier	to	prescribing	as	well	as	any	future	research.
4.6 | Cost and policy implication
Future	 research	would	benefit	 from	 incorporating	 cost‐effectiveness	
analysis.	 It	 is	often	argued	 that	LAIs	 reduce	 relapse	and	 thus	 reduce	
healthcare	cost;	however,	this	meta‐analysis	shows	no	significant	dif‐
ference	 in	 study‐defined	 relapse	 rate	when	 SGA	LAIs	 are	 compared	
with	active	control.	The	cost	of	SGA	LAIs	is	significantly	more	than	the	
oral	equivalent,	 for	example,	 in	 the	UK,	 risperidone	LAI	50	mg	costs	
around	£3700	per	patient	per	year	compared	to	less	than	£20	for	oral	
risperidone.	Similarly,	oral	aripiprazole	30	mg	per	day	costs	around	£48	
per	patient	per	year	compared	to	approx.	£2640	for	aripiprazole	LAI.	
Although	drug	price	structure	is	different	in	the	US	and	Australia	and	
price	 can	 vary	widely,	 risperidone	 LAI	 (50	mg	 fortnightly/per	 patient	
per	year)	cost	roughly	around	US	$23000	(≈£17500)	in	the	US	and	Aus	
$5500	(≈£3100)	in	Australia	and	aripiprazole	LAI	(400	mg	monthly/per	
patient	per	year)	costing	roughly	around	US	$26000	(≈£19800)	in	the	
US	and	Aus	$4500	(≈£2500)	in	Australia.	Equivalent	oral	dose	is	avail‐
able	at	a	fraction	of	the	cost.	The	results	from	this	meta‐analysis	fail	to	
support	the	use	of	SGA	LAIs	instead	of	oral	antipsychotics	on	health	
economic	grounds	and	further	research	is	required	to	provide	the	evi‐
dence	for	policymakers.	The	significantly	higher	cost	of	SGA	LAIs	will	
have	policy	implications.	Thus,	it	is	prudent	that	further	research	look‐
ing	into	SGA	LAIs	use	in	bipolar	disorder,	particularly	comparing	with	
oral	active	control	is	conducted	to	provide	evidence‐based	recommen‐
dations	to	policymakers.	In	general,	when	patency	of	a	drug	expires	the	
price	of	that	drug	drops	significantly	due	to	the	availability	of	generic	
drug.	However,	despite	patency	for	risperidone	LAI	expiring	in	2014,	no	
generic	formulation	has	become	available.	This	is	likely	to	be	due	to	the	
complexity	in	formulation	technology	and	cost	involved	in	manufactur‐
ing.	But	 if	 and	when	generic	SGA	LAIs	become	available,	 the	cost	 is	
likely	to	drop	significantly.
5  | CONCLUSION
Preventing	relapse	in	bipolar	disorder	is	a	primary	concern	for	patients	
and	healthcare	professionals	alike.	SGA	LAIs	may	have	a	role	in	bipo‐
lar	 patients	 with	 known	 adherence	 problems	 with	 oral	 medication.	
However,	 this	 meta‐analysis	 suggests	 that	 SGA	 LAIs	 is	 better	 only	
compared	to	placebo	and	not	active	control.	Considering	the	significant	
cost	pressure	and	other	issues	which	come	with	prescribing	SGA	LAIs,	
further	high‐quality	active	control	studies	are	required	to	guide	clinical	
practice.
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